Skip to main content
logo
Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.120
+0.010 (0.47%)
At close: Aug 11, 2026, 4:00 PM EDT
2.130
+0.010 (0.47%)
Pre-market: Aug 12, 2026, 8:00 AM EDT

Grace Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Market Cap
457431---
Market Cap Growth
0.22%137.21%----
Enterprise Value
27.6257.219.14000
Last Close Price
2.124.632.28---

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PB Ratio
0.531.160.47---
P/TBV Ratio
2.395.231.59---

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Debt / Equity Ratio
-0000.010.00
Net Debt / Equity Ratio
-0.27-0.27-0.33-0.37-0.40-0.40
Net Debt / EBITDA Ratio
1.531.531.331.790.532.78
Net Debt / FCF Ratio
1.911.911.491.861.722.52
Quick Ratio
7.927.9211.5314.098.4113.56
Current Ratio
8.108.1011.7714.268.5913.89
Return on Equity (ROE)
-14.74%-14.55%-19.89%-19.82%-48.15%-11.98%
Return on Assets (ROA)
-16.39%-15.98%-22.96%-14.76%-40.99%-15.31%
Return on Invested Capital (ROIC)
-23.79%-24.24%-40.09%-28.37%-80.75%-48.81%
Return on Capital Employed (ROCE)
-16.82%-16.46%-23.54%-17.45%-51.88%-16.74%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Buyback Yield / Dilution
-36.59%-36.60%-26.85%-28.16%-21.09%-148.46%
Total Shareholder Return
-36.59%-36.60%-26.85%-28.16%-21.09%-148.46%
SEC Filings: 10-K · 10-Q